Technical analysis of Alzamend Neuro Inc (ALZN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a meth...
Price Performance
| 1 month | +20.39% |
| 3 months | +50.00% |
| Year-to-date | +0.55% |
| 1 year | -26.80% |
| 3 years | -99.40% |
| 5 years | -99.95% |
52-Week Range
| 52-week High | $2.68 |
| 52-week Low | $0.84 |
| Avg Volume (90d) | 136K |
Technical Indicators
| SMA 50 | $1.47 |
| SMA 200 | $1.58 |
| 30-day Volatility (annualised) | 46.0% |
| Price vs SMA 50 | +24.6% |
| Price vs SMA 200 | +15.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.53 | |
| 2025-11 | $2.19 | -13.4% |
| 2025-12 | $1.82 | -16.9% |
| 2026-01 | $2.15 | +18.1% |
| 2026-02 | $2.01 | -6.5% |
| 2026-03 | $1.06 | -47.3% |
| 2026-04 | $1.14 | +7.5% |
| 2026-05 | $1.19 | +4.4% |
| 2026-06 | $1.20 | +0.8% |
| 2026-07 | $1.31 | +9.2% |
| 2026-08 | $1.60 | +22.1% |
| 2026-09 | $1.83 | +14.4% |
Price
| Price | $1.83 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.33 |
| EV / EBITDA | -0.64 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.31 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -57.29 |